32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for cancer, and cardiovascular, metabolic and psychiatric disorders.
The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on Hsp90 inhibitors and Hsp70 inducers, such as KU-32 and KU-174 (University of Kansas); natural products in drug design, such as minnelide (University of Minnesota) and tylocrebrine; novel compounds from Merck for metabolic and cardiovascular diseases, such as MK-7725, a series of DDP4 inhibitors and KV1.5 ion channel antagonists; and the discovery of the VEGFR2 kinase inhibitor AMG-429 (Amgen Inc).
Gater
Deborah
D
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. deborah.gater@thomsonreuters.com.
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D015195:Drug Design; D015507:Drugs, Investigational / Q000627:therapeutic use*; D018840:HSP70 Heat-Shock Proteins / Q000819:agonists; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D051666:Kv1.5 Potassium Channel / Q000037:antagonists & inhibitors; D001523:Mental Disorders / Q000188:drug therapy*; D008659:Metabolic Diseases / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
D015507:Drugs, Investigational; D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D051666:Kv1.5 Potassium Channel; D040301:Vascular Endothelial Growth Factor Receptor-2